Many significant regulatory changes are on the way which will govern how pharmaceutical & biotech firms market & sell their products. Some have referred to the changes as a broad and multifaceted attack on advertising promotions and pricing models. Many states have independently adopted policies that may have a broader impact as other states consider enacting similar laws. States like Vermont already limit the amount pharmaceutical and biotech companies can spend marketing. Washington DC’s Health SafeRx ACT aims to require pharmaceutical sales representatives to be licensed in order to sell products to doctors, clinics and others. Some states require an annual disclosure of marketing budgets. Other laws pending such as the Sunshine Act propose many sweeping changes to the landscape. These critical regulatory changes will have a huge impact on the pharmaceutical and biotech marketing. Companies may have to consider completely overhauling their marketing & training programs to remain in compliance.
The Knowledge Group is producing a LIVE web cast which will explore the issues and concerns surrounding this change and will provide valuable information analysis and best practices. Critical Regulatory Changes Governing the Marketing of Pharmaceuticals & Biotech Products - How Will It Affect Your Firm? LIVE Webcast is a must attend for: Pharmaceutical & Biotech Companies and their Marketing and Sales Teams, Risk Managers, Consultants, Industry Attorneys, and watchers.
Course Level: Intermediate
Prerequisite: None
Method Of Presentation: Group-Based-Internet
Developer: The Knowledge Conference
Recommended CLE/CPE Hours: 2.0
(Please note, your State Bar or Accounting Board will make the final determination with respect
to continuing education credit.)
Advance Preparation: Print and review course materials
Course Code: 093867
Arnold I. Friede, Esq.
Counsel, Former Associate Chief Counsel, Food and Drug Administration
Kelly N. Reeves
Partner
Robert N. Weiner, Esq.
Partner, Former Senior Counsel, White House Counsel's Office
James E. Dutton
President Emeritus, CMR Institute, Executive Advisor, Advocacy and Strategic Development, Medical Representatives, Certification Commission
Arnold I. Friede, Esq., Counsel, Former Associate Chief Counsel, Food and Drug Administration, McDermott Will & Emery LLP
- Set the stage – Current Enforcement and regulatory Environment
Robert N. Weiner, Esq., Partner, Former Senior Counsel, White House Counsel's Office, Arnold & Porter
** Speaker Agenda to be added soon.. **
Kelly N. Reeves, Partner, King & Spalding LLP
- Key requirements of state marketing cost disclosure laws, state marketing code of conduct laws, state gift ban laws, and the D.C. SafeRx Act detailer licensing law
- Putting these state law requirements into context -- pending state legislation, the federal Physician Payments Sunshine Act
- What are the trends in new state marketing laws and practical compliance challenges that industry face?
James E. Dutton, President Emeritus, CMR Institute, Executive Advisor, Advocacy and Strategic Development, Medical Representatives, Certification Commission, CMR
- Safe Rx Act – What happened and will it make a difference in patient care?
- Industry Reaction – diversity of response
- Lessons Learned – What could be done differently?
- Implications Going Forward
- Proactive Solutions and the” window of opportunity”
- Healthcare - Pharmaceutical Companies
- Chief Marketing Officers
- Sales Directors
- Risk Managers
- Consultants
- Pharmaceutical Industry Attorneys
This is a must attend event for anyone interested in understanding Marketing of Pharmaceuticals & Biotech Products.
- New guidance explained by the most qualified key leaders & experts
- Hear directly from key regulators & thought leaders
- Interact directly with panel during Q&A